• The patient is informed of and voluntarily signs the informed consent form (ICF).
• Age 18 years or older, regardless of sex.
• Confirmed diagnosis of primary light-chain (AL) amyloidosis according to 2021 guidelines.
• Measurable disease at screening defined as difference between involved and uninvolved free light chains (dFLC) ≥50 mg/L, or serum involved free light chain ≥50 mg/L with abnormal kappa:lambda ratio.
• ECOG performance status of 2 or less.
• Adequate organ function within 3 days prior to first dose, including specific blood counts, liver enzymes, bilirubin, coagulation, and kidney function as defined.
• Male and female patients of childbearing potential and their partners must agree to use effective contraception during treatment and for at least 3 months after.
• Male patients must agree not to donate sperm from screening until 90 days after last dose.
• Willing and able to comply with all study procedures and follow-up visits.
• Women not of childbearing potential are eligible; women of childbearing potential must have a negative serum or urine β-hCG pregnancy test at screening.
• Male subjects must agree to use condoms during sexual intercourse with women of childbearing potential and have no plans to father a child from signing consent until 3 months after last dose.

History of severe allergic reactions to study medication Currently pregnant or breastfeeding Recent participation in another clinical trial within the last 30 days Presence of uncontrolled medical conditions that could affect safety